期刊
PHARMACOGENOMICS JOURNAL
卷 17, 期 6, 页码 528-534出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2016.46
关键词
-
资金
- Dhont Family Foundation
- San Pedro Peninsula Cancer Guild
- Erwin Schrodinger fellowship from the Austrian Science Fund
- Swiss Cancer League [BIL KLS-3334-02-2014]
- German Cancer Aid (the Mildred-Scheel Foundation)
- Rio Hortega Research Grant from the Insituto de Salud Carlos III [CM11/00102]
- National Cancer Institute
- [P30CA014089]
Immunomodulator-targeting therapies are under development in gastric cancer (GC). However, the role of genes modulating antitumor immunity in GC remains poorly understood. We investigated the association of variations in genes involved in immunomodulatory pathways with overall survival (OS) in locoregional GC patients. Extracted genomic DNA was analyzed for 35 functional single-nucleotide polymorphisms in genes, PDCD1, CD274, CTLA4, FOXP3, LAG3, ADORA2A, NT5E and IDO1, in 162 Japanese patients as discovery set and 277 US patients as validation set. The C allele of PDCD1 rs10204525 had univariate and multivariable associations with shorter OS in Japanese cohort (P = 0.015, P = 0.043, respectively). In US cohort the C allele predicted worse OS (P = 0.007). Univariate and multivariable analyses revealed IDO1 rs9657182 associated with OS in the Japanese cohort; moreover, the association was confirmed in the US cohort. Genetic predisposition of the host in the immunomodulators may serve as a prognostic biomarker in patients with locoregional GC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据